These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reverse Genetics Approaches to Control Arenavirus. Martínez-Sobrido L; Cheng BY; de la Torre JC Methods Mol Biol; 2016; 1403():313-51. PubMed ID: 27076139 [TBL] [Abstract][Full Text] [Related]
3. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein. Cheng BYH; Nogales A; de la Torre JC; Martínez-Sobrido L Virology; 2017 Jan; 501():35-46. PubMed ID: 27855284 [TBL] [Abstract][Full Text] [Related]
4. Arenavirus reverse genetics for vaccine development. Ortiz-Riaño E; Cheng BYH; Carlos de la Torre J; Martínez-Sobrido L J Gen Virol; 2013 Jun; 94(Pt 6):1175-1188. PubMed ID: 23364194 [TBL] [Abstract][Full Text] [Related]
5. Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells. Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L J Vis Exp; 2013 Aug; (78):. PubMed ID: 23928556 [TBL] [Abstract][Full Text] [Related]
6. Reverse genetics approaches to combat pathogenic arenaviruses. de la Torre JC Antiviral Res; 2008 Dec; 80(3):239-50. PubMed ID: 18782590 [TBL] [Abstract][Full Text] [Related]
7. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines. Martinez-Sobrido L; de la Torre JC Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328 [TBL] [Abstract][Full Text] [Related]
8. Development of live-attenuated arenavirus vaccines based on codon deoptimization. Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652 [TBL] [Abstract][Full Text] [Related]
9. [Progess in the development of VLPs vaccine]. Cao L; Bi SL Bing Du Xue Bao; 2011 Jul; 27(4):378-82. PubMed ID: 21874909 [No Abstract] [Full Text] [Related]
10. Rhabdoviruses as vectors for vaccines and therapeutics. Scher G; Schnell MJ Curr Opin Virol; 2020 Oct; 44():169-182. PubMed ID: 33130500 [TBL] [Abstract][Full Text] [Related]
11. Viral vectors as vaccine platforms: deployment in sight. Rollier CS; Reyes-Sandoval A; Cottingham MG; Ewer K; Hill AV Curr Opin Immunol; 2011 Jun; 23(3):377-82. PubMed ID: 21514130 [TBL] [Abstract][Full Text] [Related]
12. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines. Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555 [TBL] [Abstract][Full Text] [Related]
16. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses. Iwasaki M; Cubitt B; Sullivan BM; de la Torre JC J Virol; 2016 Jan; 90(6):3187-97. PubMed ID: 26739049 [TBL] [Abstract][Full Text] [Related]